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Objectives To evaluate the current seroprevalence of antibodies against hepatitis A virus (HAV) in a sample of schoolchildren above
10 years of age and to determine the prevalence of HAV-induced hepatitis in adults at a tertiary care hospital in northern India between
January 1992 and December 2000.
Methods Sera from 276 male and 224 female schoolchildren aged 10–17 years were tested for anti-HAV antibodies by enzyme-linked
immunosorbent assay. Consecutive patients with a diagnosis of acute viral hepatitis who attended a liver clinic were tested for the
serological markers of HAV, hepatitis B Virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus.
Findings Of the male and female children, 96.3% and 98.2%, respectively had anti-HAV antibodies in their sera. The prevalence of
these antibodies in the age groups 10–12, 13–14, and 15–17 years were 98.6%, 94.8%, and 98.3% respectively. The frequency of
HAV-induced acute viral hepatitis (69/870, 8%) in adults did not show an increasing trend.
Conclusion Mass HAV vaccination may be unnecessary in northern India because the seroprevalence of protective antibodies against
HAV in schoolchildren aged over 10 years remains above 95% and there has been no apparent increase in HAV-induced acute viral
hepatitis in adults.
Keywords Hepatovirus/immunology; Hepatitis antibodies/immunology; Hepatitis B surface antigens; Hepatitis, Viral, Human/
virology; Child; Adult; Seroepidemiologic studies; India (source: MeSH, NLM ).
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Introduction
The hepatitis A virus (HAV) is an enterically transmitted
hepatotropic virus and is themajor cause of acute viral hepatitis
(AVH) in children (1). In areas of high endemicity most
children are exposed to the virus and the consequent
acquisition of antibodies against the virus confers lifelong
immunity (2).
During the last five years, several reports from countries
in southernAsia, LatinAmerica, andEurope have documented
a decreasing seroprevalence of protective antibodies against
HAV (3–8). This change has been brought about by improved
hygiene and sanitation in these countries, where the decreased
exposure of children to water and food contaminated with
HAV has resulted in a higher incidence of HAV infection
among adults. HAV infection in non-exposed adults causes
more severe and prolonged disease (9–12). Safe and highly
immunogenic vaccines (13, 14) are now available and mass
HAV vaccination of children is being recommended in regions
of low endemicity (15).
In India the seroprevalence of HAV antibodies exceeds
90% in adults (16). However, there have been recent reports of
a decreasing prevalence of HAV in this country, suggesting
that the seroprevalence of HAV antibodies is becoming similar
to that in the industrialized world (17, 18). Consequently, HAV
vaccination has been recommended for schoolchildren and
adults (19). The sample size of children in studies conducted in
India has been small. The study from Mumbai (18) sampled
children from a population who came to hospital for the
treatment of non-gastrointestinal diseases. A study fromDelhi
(17) included a sample of the adult population only. Clearly,
seroprevalence data relating to the healthy paediatric popula-
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tion are necessary in order to assess the need for routine or
mass vaccination. The present study was therefore designed to
evaluate the seroprevalence of HAV antibodies in an adequate
sample of schoolchildren aged 10–17 years in two government
schools in Delhi. We also evaluated the prevalence of HAV-
induced hepatitis with onset in adulthood between January
1992 and December 2000 in a tertiary care referral centre for
liver disease, with a view to determining whether any change
had occurred in its incidence.
Methods
The two schools in Delhi were chosen because the subjects
were the children or wards of central government employees
from various regions of the country and belonged to a wide
range of socioeconomic strata. The age range of the 276 boys
and 224 girls was 10–17 years.
Departmental and institutional ethical clearance for the
study was obtained. Permission was granted by the school
authorities and consent for medical examination and blood
sampling was obtained from the parents of all the children
involved.
A history of any serious medical illness, including jaundice,
was obtained and a thorough physical examination was
performed. A sample of 5–7 ml of blood was drawn from every
child and standard laboratory methods were employed to test for
haemoglobin, total leukocytes, liver function, hepatitis B surface
antigen (HBsAg), and total antibodies to HAV. The serological
markers (HBsAg and anti-HAV antibodies) were investigated by
enzyme-linked immunosorbent assay (ELISA) with commer-
cially available kits (Organon Teknika, The Netherlands).
Assuming 90% seropositivity of anti-HAV antibody
among children aged over 10 years, we calculated that a sample
size of 144 children would be adequate with an a error of 5%
(95% confidence) and a precision of 5% for the estimation of
prevalence.
In order to evaluate the prevalence of HAV-induced
acute viral hepatitis (AVH) among the adult population we
analysed consecutive patients diagnosed as having AVH who
attended the liver clinic between January 1992 and December
2000. The diagnosis of AVH was based on the clinical profile,
biochemical tests, and serological tests for hepatotropic viral
infections. Each patient diagnosed as having AVH was tested
for HBsAg, IgM antibody to hepatitis B core antigen (IgM anti
HBc), antibody to hepatitis C virus (anti HCV), IgM antibody
to hepatitis E virus (IgM anti HEV), and antibody to
hepatitis D virus (anti HDV) by ELISA. Those patients who
were positive for IgM anti-HAV were diagnosed as cases of
HAV-induced AVH.
Results
Anti-HAV antibodies were present in 486 of the 500 children
(97.2%) (Table 1). Of the 500 children, 178 (35.6 %) were aged
15–17 years, 174 (34.8 %) were aged 13–14 years, and
148 (29.6%) were 10–12 years of age; seropositivity for anti-
HAV antibodies was detected in 175 (98.31%), 165 (95%), and
146 (98.6%) of the children in the respective age groups
(P = 0.33) (Table 1). In adults the incidence of AVH
attributable to HAV did not increase (Table 2). Between
January 1992 and December 2000, 870 diagnosed cases of
AVH were registered in the liver clinic and 69 (8%) of them
were attributable to HAV.
Discussion
The prevalence of protective antibodies against HAV among
schoolchildren aged 10–17 years was 97.2%, and was similar in
the age groups 10–12, 13–14, and 15–17 years and in boys and
girls (Table 1). This indicated that, by the time they were
10 years of age, most of the children had acquired anti-HAV
antibodies, in accordance with the expected pattern of HAV
seroprevalence in a region of high endemicity (20). Similar
results have been reported from Lucknow (n = 73), where the
seroprevalence of anti-HAV antibodies was 91% in children
aged 6–10 years and 96% in those aged 11–18 years (21). In
Delhi the seroprevalence of anti-HAV antibodies was reported
to be 80% by the age of 10 years (n = 420) (22). No change in
the seroprevalence of anti-HAV antibodies was detected in
Pune between 1982 and 1992 (23). Patterns of endemicity
similar to that in the present study have been found in other
developing countries, where, despite improvements in gross
national product, the seroprevalence of anti-HAV antibodies
remains high (24).
However, two recent Indian studies have indicated lower
seroprevalences of anti-HAV antibodies in schoolchildren (17,
Table 1. Number and frequency of schoolchildren seropositive
for anti-HAVa antibodies by age and sex
Age in years /sex No. of children seropositive for
anti-HAV antibodies
10–12 (n = 148) 146 (98.6)b
Male (n = 76) 74 (97.3)
Female (n = 72) 72 (100)
13–14 (n = 174) 165 (94.8)
Male (n = 94) 89 (94.6)
Female (n = 80) 76 (95)
15–17 (n = 178) 175 (98.3)
Male (n = 106) 103 (97.1)
Female (n = 72) 72 (100)
Total (n = 500) 486 (97.2)
Male (n = 276) 266 (96.3)
Female (n = 224) 220 (98.2)
a HAV = hepatitis A virus.
b Figures in parentheses are percentages.
Table 2. Annual number and frequency of acute viral hepatitis
(AVH) and HAVa-induced AVH in adults, 1992–2000
Year AVH HAV-induced
AVH
1992 24 3 (12.5)b
1993 91 10 (10.9)
1994 95 5 (5.26)
1995 94 11 (11.7)
1996 158 15 (9.4)
1997 116 11 (9.4)
1998 56 8 (14.2)
1999 120 5 (4.6)
2000 116 1 (8.0)
Total 870 69 (8.0)
a HAV = hepatitis A virus.
b Figures in parentheses are percentages.
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18). In Delhi an anti-HAV antibody prevalence of 36.7% was
reported among 500 adults (17). In a study involving 284
children and 386 adults in Mumbai it was found that 50% of
children belonging to families of high socioeconomic status did
not possess immunity against HAV infection (18). Both of
these studies were hospital based and included subjects
attending hospital for treatment of non-gastrointestinal
diseases. Thus they were not representative of healthy
schoolchildren, in whom the assessment of seroprevalence
of anti-HAV antibodies would influence the strategy of mass
HAV vaccination. The present study was based on a large
sample and included children belonging to a wide range of
socioeconomic strata. The results of the three Indian studies
cited above (21–23) were similar to those of the present one. It
appears that at least 90% of Indian children acquire protective
antibodies against HAV by the age of 10 years.
Any reduction in the seroprevalence of anti-HAV
antibodies among Indian schoolchildren during the last decade
would be expected to have produced a rise in the annual
incidence of HAV-induced AVH in the adult population, at
least at the referral centres for liver disease in northern India.
However, the etiological analysis of the AVH patients
registered at our liver clinic between 1992 and 2000 did not
reveal an increasing trend of HAV-induced AVH (Table 2). A
multicentre study conducted in India during the late 1980s
revealed that HAV was the etiological agent in 70 out of 1243
adult AVH patients (6%) (25). The present study indicated that
HAV played the same role in 8% of cases of AVH in adults
(n = 870) registered at our centre between 1992 and 2000.
Therefore, during the last two decades there has been evidently
no change in the proportion of HAV-induced AVH among
adults in India.
Further studies may be necessary in order to determine
precisely when, between the ages of 1 and 9 years, children in
northern India acquire anti-HAV antibodies. The study in
Lucknow revealed the presence of these antibodies in about
90% of children aged 6–10 years (21). The present study was
confined to two schools and was limited to the city of Delhi.
Affluent subgroups of the population may benefit from HAV
vaccination but themajority of the children in the present study
had acquired protective antibodies against the virus by the time
they went to school. In these circumstances, mass vaccination
against HAV may not be cost-effective in a population where
HAV is highly endemic. The general pattern seen in developing
countries is that exposure to HAV is virtually universal before
the age of 10 years (20). In rural Liberia an annual incidence of
HAV seroconversion of 45% in infants aged 1–5 years was
reported (26). In Indonesia, 95% of 9-year-old children were
naturally immune to HAV infection (24). Therefore, in
countries where HAV is highly endemic, mass vaccination
against the virus may not be necessary, and large population-
based studies involving adequate sampling are needed in order
to assess whether it is appropriate. n
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Re´sume´
Re´sultats d’une enqueˆte se´ro-e´pide´miologique sur l’utilite´ de la vaccination anti-he´patite Ades e´coliers dans
le nord de l’Inde
Objectif Evaluer le taux de se´ropre´valence actuel des anticorps
dirige´s contre le virus de l’he´patite A (HAV) chez un e´chantillon
d’e´coliers de plus de 10 ans et de´terminer la pre´valence de
l’he´patite induite par le HAV chez l’adulte dans un e´tablissement
hospitalier de niveau tertiaire dans le nord de l’Inde entre
janvier 1992 et de´cembre 2000.
Me´thodes Le se´rum de 276 e´coliers et 224 e´colie`res de 10 a`
17 ans a e´te´ examine´ a` la recherche d’anticorps anti-HAV au
moyen d’un test ELISA (enzyme-linked immunosorbent assay =
titrage au moyen d’un immunoadsorbant lie´ a` une enzyme). Les
marqueurs se´rologiques des HAV, HBV, HCV, HDV et HEV ont
e´te´ recherche´s chez les patients conse´cutifs ayant un diagnostic
d’he´patite virale aigue¨ consultant dans un service d’he´patologie.
Re´sultats Les anticorps anti-HAV e´taient pre´sents dans le
se´rum de 96,3 % des garc¸ons et 98,2 % des filles. La pre´valence
de ces anticorps dans les classes d’aˆge 10-12 ans, 13-14 ans
et 15-17 ans e´tait respectivement de 98,6 %, 94,8 % et 98,3 %.
Aucune tendance a` l’augmentation de la fre´quence des
he´patites virales aigue¨s induites par le HAV chez l’adulte n’a e´te´
note´e (69/870, soit 8 %).
Conclusion La vaccination de masse contre le HAV pourrait eˆtre
inutile dans le nord de l’Inde, dans la mesure ou` la se´ropre´valence
des anticorps protecteurs anti-HAV reste supe´rieure a` 95% chez les
e´coliers de plus de 10 ans et ou` aucune augmentation apparente
des he´patites virales aigue¨s induites par le HAV n’est observe´ chez
l’adulte.
Resumen
La vacunacio´n contra la hepatitis A, tal vez innecesaria entre los escolares del norte de la India: resultados
de una encuesta seroepidemiolo´gica
Objetivo Evaluar la actual seroprevalencia de anticuerpos contra
el virus de la hepatitis A (VHA) en una muestra de escolares de ma´s
de 10 an˜os de edad, y determinar la prevalencia de hepatitis por
VHA entre los adultos en un hospital de atencio´n terciaria del norte
de la India entre enero de 1992 y diciembre de 2000.
Me´todos Se utilizo´ la prueba de inmunosorcio´n enzima´tica para
analizar los sueros de una muestra de escolares (276 varones y
224 mujeres) de 10-17 an˜os a fin de determinar el nivel de
anticuerpos anti-VHA. Se analizo´ adema´s el suero de una serie de
pacientes consecutivos con diagno´stico de hepatitis vı´rica aguda que
acudieron a un consultorio de atencio´n hepa´tica, para determinar los
marcadores serolo´gicos de los virus VHA, VHB, VHC, VHD y VHE.
Resultados Entre los escolares, el 96,3% y el 98,2% de los
nin˜os y las nin˜as, respectivamente, presentaban anticuerpos
anti-VHA en el suero. La prevalencia de estos anticuerpos en los
grupos de edad de 10-12, 13-14 y 15-17 an˜os fue del 98,6%,
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94,8% y 98,3%, respectivamente. La frecuencia de hepatitis vı´rica
aguda por VHA (69/870, 8%) en los adultos no revelo´ una
tendencia al aumento.
Conclusio´n Considerando que la seroprevalencia de anticuerpos
protectores contra el VHA observada entre los escolares de ma´s de
10 an˜os permanece por encima del 95%, y que no se da un
aumento claro de los casos de hepatitis vı´rica aguda por VHA en los
adultos, es posible que la vacunacio´n masiva contra el VHA sea
innecesaria en el norte de la India.
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